Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2402419 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment With Lorlatinib Monotherapy for Secondary Central Nervous System Oligometastatic Disease in Refractory Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer.
Cureus
November 2024
Hematology and Medical Oncology, Tripler Army Medical Center, Honolulu, USA.
The anaplastic lymphoma kinase (ALK) gene plays crucial roles in both normal brain development and oncogenesis, particularly in non-small cell lung cancer (NSCLC). Metastatic ALK-positive NSCLC is characterized by ALK tyrosine kinase domain rearrangements, prompting the use of ALK tyrosine kinase inhibitors (TKIs) to target the mutation. While first-line treatment options include alectinib, brigatinib, and lorlatinib per National Comprehensive Cancer Network (NCCN) guidelines, therapeutic challenges arise in cases of disease progression.
View Article and Find Full Text PDFCase report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer.
Front Oncol
November 2024
Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel.
Background: Over the past decade, progress in the diagnosis and treatment of Non-Small Cell Lung Cancer (NSCLC) has led to the identification of many targeted mutations. This has enhanced PFS and OS in both advanced and early-stage NSCLC. The current standard of care for stage III NSCLC varies, and it may combine chemotherapy with either immunotherapy or radiotherapy.
View Article and Find Full Text PDFLong-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report.
Case Rep Oncol
August 2024
Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) are at increased risk of central nervous system (CNS) metastasis at initial diagnosis and throughout treatment. In a phase 3 trial, lorlatinib, a third-generation ALK tyrosine kinase inhibitor, significantly improved progression-free survival. In further analysis, lorlatinib revealed superior intracranial efficacy and prolonged time to intracranial progression compared with crizotinib.
View Article and Find Full Text PDFTaiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.
Target Oncol
November 2024
Institute of Medicine, Chung Shan Medical University, No. 110, Sect. 1, Jianguo N. Road, Taichung, 402, Taiwan.
Background: The clinical outcomes of patients with anaplastic lymphoma kinase-positive (ALK+) advanced lung adenocarcinoma vary according to real-world data.
Objective: In this study, we aimed to investigate the treatment discontinuation (TTD) and overall survival (OS) of patients with ALK+ advanced lung adenocarcinoma treated with first-line ALK-TKIs in Taiwan.
Patients And Methods: This retrospective study evaluated all advanced lung adenocarcinoma patients registered in the National Taiwan Cancer Registry from 2017 to 2020 who had ALK rearrangement and received ALK-TKI treatment, using data from Taiwan's National Health Insurance Research Database (NHIRD).
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
Lung Cancer
November 2024
Pfizer Inc., NY, USA. Electronic address:
Article Synopsis
- Next-generation ALK tyrosine kinase inhibitors (TKIs) like alectinib, brigatinib, and lorlatinib show better progression-free survival compared to chemotherapy or crizotinib for first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC).
- The study conducted a network meta-analysis (NMA) to compare the efficacy of lorlatinib with other ALK TKIs, focusing on progression-free survival and other outcomes, using data from ten trials.
- Results indicated lorlatinib significantly improved progression-free survival compared to both alectinib and brigatinib, supporting its use as an effective first-line treatment for this type of lung cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!